Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14738266 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2EPHX2KMT2AKDM4EMAPT | |
| SCHEMBL482065 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2EPHX2KMT2AKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL3266707 | 0.97 | SMN1; SMN2 (0.41) | SMN1; SMN2EPHX2KMT2AKDM4EMAPT | |
| SCHEMBL13332956 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2AKDM4EMAPTATM | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL5661 | 0.87 | — | — | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL6927157 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2AKDM4EMAPTATM | |
| SCHEMBL28418543 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2AKDM4EMAPTATM | |
| SCHEMBL9797557 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2AKDM4EMAPTATM | |
| SCHEMBL383436 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2AKDM4EMAPTATM | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL11534774 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | claimed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | claimed |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | claimed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | claimed |
| EP-1633348-B1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2008-10-08 | — | — | EP | claimed |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | claimed |
| EP-1633348-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | claimed |
| WO-2004098589-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| US-5411989-A | Cardiovascular disorders | BOEHRINGER MANNHEIM, GMBH (DE) | 1995-05-02 | — | — | US | claimed |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | VTV THERAPEUTICS LLC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | VTV THERAPEUTICS LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250136591-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250082614-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | CYTEIR THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| CN-114514023-B | Methods of treating pancreatic cancer using RAD51 inhibitors | 赛泰尔治疗公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004080973-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-23 | — | — | WO | disclosed |
| US-5411989-A | Cardiovascular disorders | BOEHRINGER MANNHEIM, GMBH (DE) | 1995-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | SMN1; SMN2 3553/4885EPHX2 2246/4885KMT2A 3940/4885 |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | CSF1R, CD209, NFATC1 | SMN1; SMN2 4666/4885EPHX2 2350/4885KMT2A 1474/4885 |
| US-20250082614-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | RAD51, MRE11, RAD52 | SMN1; SMN2 1418/4885EPHX2 2795/4885KMT2A 2280/4885 |
| US-20250136591-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | SMN1; SMN2 245/4885EPHX2 3010/4885KMT2A 1618/4885 |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | HBB, HBZ, HBG1 | SMN1; SMN2 7/4885EPHX2 1715/4885KMT2A 669/4885 |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | CTSG, CTSD, CTSB | SMN1; SMN2 3634/4885EPHX2 2649/4885KMT2A 3854/4885 |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, CNR1 | SMN1; SMN2 3662/4885EPHX2 1218/4885KMT2A 2589/4885 |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | SMN1; SMN2 4550/4885EPHX2 3106/4885KMT2A 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.